Literature DB >> 28067759

Effective Synthesis of Nucleosides Utilizing O-Acetyl-Glycosyl Chlorides as Glycosyl Donors in the Absence of Catalyst: Mechanism Revision and Application to Silyl-Hilbert-Johnson Reaction.

Chengyuan Liang1, Weihui Ju2, Shunjun Ding3, Han Sun4, Gennian Mao5.   

Abstract

An effective synthesis of nucleosides using glycosyl chlorides as glycosyl donors in the absence of Lewis acid has been developed. Glycosyl chlorides have been shown to be pivotal intermediates in the classical silyl-Hilbert-Johnson reaction. A possible mechanism that differs from the currently accepted mechanism advanced by Vorbrueggen has been proposed and verified by experiments. In practice, this catalyst-free method provides easy access to Capecitabine in high yield.

Entities:  

Keywords:  N-glycosylation; catalyst free reaction; glycosyl chiorides; nucleosides; silyl-Hilbert-Johnson reaction

Mesh:

Substances:

Year:  2017        PMID: 28067759      PMCID: PMC6155650          DOI: 10.3390/molecules22010084

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


1. Introduction

Nucleoside analogs represent a potentially important class of antiviral anticancer agents [1,2,3,4,5] with antimicrobial and cholinesterase inhibitory activities [6,7,8,9,10] and are commonly used to treat hepatitis B virus [11,12], hepatitis C virus [13,14], herpes simplex [15,16], Human Immunodeficiency Virus (HIV) and neoplasms [17,18]. Zalcitabine (2′,3′-dideoxycytidine, ddc), Abacavir, Stavudine (2′,3′-didehydro-2′,3′-didehydro-2′,3′-dideoxythymidine, d4T), Didanosine (2′,3′-dideoxyinosine, ddI), Emtricitabine (FTC) and Zidovudine (azidothymidine, AZT) (Figure 1) are among the essential antiretroviral nucleoside analogue reverse transcriptase inhibitors (NRTIs) that are used to treat HIV/Acquired Immune Deficiency Syndrome (AIDS) infections [19]. In addition, some nucleoside analogues can function as both NRTIs and polymerase inhibitors for other viruses (e.g., Entecavir for hepatitis B) [20]. Less selective nucleoside analogues are used as chemotherapeutic agents to treat cancer, such as the orally administered Capecitabine [21], which is used to treat metastatic breast and colorectal cancers, and Cytarabine [22], which is mainly used in the therapy of white blood cell carcinomas (i.e., acute myeloid leukemia and non-Hodgkin’s lymphoma) (Figure 1). Consequently, the development of new and more effective methods for developing nucleoside analogs is of significant commercial and academic interest.
Figure 1

Structures of commonly used nucleoside drugs.

Well-established strategies of preparing N-nucleosides include the following: (1) Fischer and Helferich reported that purine nucleosides could be synthesized by coupling purines with acetobromoglucose and applying silver or mercury salts as catalysts [23,24]; (2) the improved silyl-Hilbert-Johnson reaction [25,26], the most widely used synthetic method, involves the coupling of per-silylated heterocyclic bases with per-acylated sugars in the presence of Friedel-Crafts catalysts (e.g., SnCl4 or TMSOTf). This reaction has been the dominant method for the preparation of pyrimidine, purine and other heterocyclic nucleosides. Despite these available methods [8,9,27,28,29,30], a facile and green synthetic strategy, which avoids the use of costly and hazardous catalysts, for synthesizing nucleosides remains an urgent need. Since the introduction of the silyl-Hilbert-Johnson reaction by Iwai and Nishimura [31], diverse types of glycosyl donors have been applied to prepare nucleosides. Among these donors, 1-O-acetyl sugars are the most frequently used glycosyl donors. However, in all of these methods, a stoichiometric amount of a strong Lewis acid promoter (e.g., SnCl4, TMSOTf or BF3·OEt2) is required to secure high-yielding N-glycosylation. Notably, 1-Cl-acetyl sugars, inexpensive glycosyl donors, have rarely been employed in nucleoside synthesis, and a catalyst-free N-glycosylation method utilizing 1-Cl-acetyl sugars as glycosyl donors has not been reported yet. Herein, we report the facile glycosylation of nucleobases employing 1-Cl-acetyl sugars as glycosyl donors under mild conditions in the absence of any additives.

2. Results and Discussion

Initially, we attempted to develop an ionic liquid-promoted method of N-glycosylation employing peracetylated d-ribofuranosyl chloride (1a) as the glycosyl donor. Disappointingly, ionic liquid was unsuitable for the labile silyl-pyrimidine in these preliminary attempts (Entries 6–8, Table 1). A farraginous mixture of products was produced, but no nucleoside was obtained, according to mass spectrometric analysis. In contrast, acetyl nucleoside (3a) was obtained with an unexpectedly high yield (95%) when the reaction was carried out in the absence of catalyst (Entry 1, Table 1). The starting material peracetylated d-ribofuranosyl chloride (1a) was conveniently prepared by the reaction of per-acylated ribose with stoichiometric thionyl chloride (instead of the commonly used acetyl chloride) in the presence of catalytic glacial acetic acid in dry 1,2-dichloroethane at ambient temperature (Figure 2). Bis-silyl pyrimidine (2a) was obtained in a quantitative yield by treating thymine with Hexamethyldisilazane (HMDS) using a catalytic amount of ammonium sulfate in refluxing 1,2-dichloroethane (DCE). Gratifyingly, these important findings encouraged us to further explore the scope of the catalyst-free reaction.
Table 1

Optimization of reaction conditions for the synthesis of 3a.

EntrySolventReaction Time (h)Temprature (°C)Yield (%)
11,2-Dichloroethane48395
2Toluene611089
3MeCN78078
4THF106664
5Ethanol1078Trace
6[Bmim]BF4890-
7[Bmim]PF6890-
8[Bmim]HSO4890-
Figure 2

Synthesis of ribosylthymine.

We commenced our study with a brief optimization of the reaction conditions, selecting peracetylated d-ribofuranosyl chloride (1a) and per-silylated thymine as starting materials. As shown in Table 1, a trace amount of 3a was obtained in a polar protic solvent (Entry 5). In contrast, reactions occurring in other solvents (i.e., DCE, MeCN, THF and toluene) at reflux afforded the desired product in moderate to excellent yields (Entries 1–4). As mentioned above, none of the desired product (3a) was obtained in ionic liquids (Entries 6–8). With the optimal reaction conditions in hand, we investigated the reactions of 1-Cl-acetyl sugars 1a and 1b with a variety of per-silylated nucleobases (2a–2g) using 1,2-dichloroethane (DCE) as solvent at 83 °C to establish the generality of the transformation. Compound 1b was obtained according to the method used to prepare 1a, and per-silylated nucleobases 2b–2g were prepared in the same manner as 2a. Reaction completion (after 6–14 h) was determined by thin-layer chromatography (TLC). The results are shown in Figure 3. The glycosylation of per-silylated pyrimidine nucleobases 2a–2d with peracetylated d-ribofuranosyl chloride 1a afforded the desired β-nucleosides 3a–3e in moderate to excellent yields (64%–95%).The electron-withdrawing group (-F) on silylated 5-fluorouracil led to a decrease in the yield of the N-glycosylation reaction (compared to 2a and 2b), likely due to the reduced nucleophilicity of 2c. Purine nucleobases 2f and 2g generated the corresponding products 3f and 3g in poor yields (14% and 18%), which might have partially been due to difficulties in purification. The coupling of per-silylated pyrimidine nucleobases 2a–2e with tetra-O-acetyl glucopyranosyl chloride 1b led to a mixture of α/β nucleoside stereoisomers 3h3l in relatively low yields (14%–44%), the ratios determined by the chiral column of HPLC. In addition, 2f and 2g failed to generate corresponding products 3m and 3n, instead resulting in a complex mixture.
Figure 3

Nucleoside synthesis employing acetyl-glycosyl chlorides as glycosyl donors.

Perhaps the most striking demonstration of the utility of this reaction is demonstrated by the preparation of Capecitabine (an oral medication for treating breast cancers). As depicted in Figure 4, key intermediate 6a was obtained employing 4b′ and 5a as starting materials with improved yield (86%, compared to 75% using a traditional silyl-Hilbert-Johnson reaction) and a significant decrease in the reaction time (4 h compared to 8 h) [32].
Figure 4

Application to the preparation of Capecitabine.

Intermediate A is quite similar to intermediate B formed under silyl-Hilbert-Johnson reaction conditions, according to the classical mechanism (path a in Figure 5) initially proposed by Vorbrueggen [33,34]. Combining this structure with our findings, the efficient and high-yielding reactions described above, indicates that intermediate A can be generated smoothly from peracetylated d-ribofuranosyl chloride 1a. Consequently, we postulate that path b (Figure 6) may be an alternative course of the classical mechanism (path a) of the silyl-Hilbert-Johnson reaction. To verify our hypothesis, per-acetyl ribose was treated with SnCl4 in the absence of per-silylated nucleobase 2a, according to silyl-Hilbert-Johnson reaction conditions. As expected, peracetylated d-ribofuranosyl chloride 1a was obtained in relatively high yield (56%) after stirring for 3 h at ambient temperature. The equivalent stoichiometric silyl-thymidine 2a without Lewis acid catalyst was added to a solution of peracetylated d-ribofuranosyl chloride 1a in DCE and the resulting mixture was stirred for 16 h at ambient temperature (Figure 6). Upon completion of the reaction, the crude product 3a was purified by column chromatography to give a moderate isolated yield of 43%. Therefore, the silyl-Hilbert-Johnson reaction might be characterized by two available routes, path a and path b. The mechanism is shown in Figure 6.
Figure 5

Mechanism for silyl-Hilbert-Johnson reaction.

Figure 6

Verification of speculated path b of silyl-Hilbert-Johnson reaction.

Figure 5 lays out a plausible mechanism for this catalyst-free N-glycosylation method. First, 1a undergoes intramolecular cyclization to give cyclic oxonium ion A; this process occurs without any catalyst. Subsequently, A reacts with 2a via an intermolecular nucleophilic substitution reaction to deliver intermediate B, which is converted to the target product 3a after the addition of water. Acidic gas, possibly from the hydrolysis of TMSCl in air, was generated in the reaction, which supports the proposed mechanism.

3. Experimental Section

All substrates and solvents were commercially available and were purified before use. Reactions were carried out under N2 using standard Schlenk techniques. Mass spectra were recorded on a mass spectrometer using electron impact ionization (EI) techniques. Compounds were visualized under UV lamp (254 nM). 1H-NMR and 13C-NMR spectra were obtained on a Bruker AV-300 NMR spectrometer (Zurich Region, Switzerland). Analytical TLC was carried out with plates pre-coated with silicagel 60 F254 (0.25 mm thick). The identity of the products was established by comparing their physical and spectral data with those of reported compounds [35,36,37,38,39,40,41]. See more details in Supplementary Materials.

General Experimental Procedure for Synthesis of Acetyl Ribosylthymine (

Synthesis of 1a: Ribofuranose tetraacetate (20 mmol) was mixed with thionyl chloride (12 mmol) and glacial acetic acid (0.1 mmol) under stirring in 1,2-dichloroethane (50 mL) for 6 h at room temperature. The obtained product was purified by column chromatography (MeOH/CH2Cl2, 1:10 v/v). Compound 1b was prepared under the same conditions with a longer reaction time (10 h). Synthesis of 2a: A mixture of thymidine (10 mmol), HMDS (12 mmol) and ammonium sulphate (0.1 mmol) was stirred in refluxing 1,2-dichloroethane (50 mL) for 3 h. When the reaction mixture became translucent, it was concentrated in vacuo to provide 2a. Compounds 2b–f were prepared under the same conditions with varying reaction times (4–8 h). Synthesis of 3a: To a solution of silyl-thymidine (10 mmol) in DCE (100 mL) was added 1a (12 mmol diluted in 25 mL DCE) dropwise at room temperature. The resulting mixture was stirred for 4 h at 83 °C. Upon completion of the reaction, as indicated by TLC (n-hexane/ethylacetate: 40:60), the reaction mixture was cooled to room temperature and H2O (50 mL) was added, and the mixture was, stirred for 0.5 h. The resulting reaction mixture was diluted with DCE (50 mL) and washed with water and saturated NaCl solution. The organic layer was dried with MgSO4 and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (MeOH/CH2Cl2, 1:10 v/v) to obtain an analytical sample for a total yield of 95%.

4. Conclusions

In summary, we have developed an efficient and straightforward synthesis of N-nucleosides employing glycosyl chlorides as glycosyl donors in the absence of traditional Lewis acid catalysts, which significantly expands the versatility of the silyl-Hilbert-Johnson reaction. The higher yields, mild reaction conditions, ease of purification, economic availability of the starting materials and avoidance of a catalyst make this an ecologically friendly procedure for the synthesis of nucleosides. A novel dual-path mechanism for the silyl-Hilbert-Johnson reaction has also been proposed and validated experimentally. In addition to Capecitabine, further expansions of the reaction scope and synthetic applications of this methodology are in progress in our laboratory.
  29 in total

1.  In vitro antibacterial activity of different adenosine analogues.

Authors:  Luca A Vitali; Dezemona Petrelli; Catia Lambertucci; Manuela Prenna; Rosaria Volpini; Gloria Cristalli
Journal:  J Med Microbiol       Date:  2011-12-08       Impact factor: 2.472

2.  Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine.

Authors:  J A Fyfe; P M Keller; P A Furman; R L Miller; G B Elion
Journal:  J Biol Chem       Date:  1978-12-25       Impact factor: 5.157

3.  An efficient approach to the synthesis of nucleosides: gold(I)-catalyzed N-glycosylation of pyrimidines and purines with glycosyl ortho-alkynyl benzoates.

Authors:  Qingju Zhang; Jiansong Sun; Yugen Zhu; Fuyi Zhang; Biao Yu
Journal:  Angew Chem Int Ed Engl       Date:  2011-04-15       Impact factor: 15.336

4.  Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes.

Authors:  J A Suzich; J K Tamura; F Palmer-Hill; P Warrener; A Grakoui; C M Rice; S M Feinstone; M S Collett
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

5.  Microwave-promoted facile and efficient preparation of N-(alkoxycarbonylmethyl) nucleobases--building blocks for peptide nucleic acids.

Authors:  Guirong Qu; Zhiguang Zhang; Haiming Guo; Mingwei Geng; Ran Xia
Journal:  Molecules       Date:  2007-03-19       Impact factor: 4.411

6.  Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.

Authors:  D L Darrington; J M Vose; J R Anderson; P J Bierman; M R Bishop; W C Chan; M E Morris; E C Reed; W G Sanger; S R Tarantolo
Journal:  J Clin Oncol       Date:  1994-12       Impact factor: 44.544

7.  Enantioselective synthesis of homo-N-nucleosides containing a 1,4-dioxane sugar analog.

Authors:  Qiang Yu; Per Carlsen
Journal:  Molecules       Date:  2008-12-03       Impact factor: 4.411

Review 8.  Exploiting the nucleotide substrate specificity of repair DNA polymerases to develop novel anticancer agents.

Authors:  Emmanuele Crespan; Anna Garbelli; Alessandra Amoroso; Giovanni Maga
Journal:  Molecules       Date:  2011-09-16       Impact factor: 4.411

Review 9.  Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.

Authors:  Tadeusz Robak; Anna Korycka; Ewa Lech-Maranda; Pawel Robak
Journal:  Molecules       Date:  2009-03-23       Impact factor: 4.411

10.  Synthesis of novel homo-N-nucleoside analogs composed of a homo-1,4-dioxane sugar analog and substituted 1,3,5-triazine base equivalents.

Authors:  Qiang Yu; Dirk Schwidom; Alexander Exner; Per Carlsen
Journal:  Molecules       Date:  2008-12-10       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.